We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Topics » Pharmaceuticals » GMPs

GMPs
%{topic} RSS Feed RSS

Indiana Compounder Indicted on Conspiracy, Drug Potency

June 28, 2017
According to the indictment, at least three infants experienced life-threatening effects. Read More

Indiana Compounder Indicted on Conspiracy, Drug Potency

June 26, 2017
Pharmakon Pharmaceuticals executives routinely sent drugs to hospitals without waiting for test results confirming the potency of the drugs matched their labels, and when results showed the strength was often nearly double what it should have been, covered up the error and lied to FDA investigators rather than notifying the FDA or customers, according to a 10-count federal indictment. Read More

Indian Drugmaker’s Products Banned from U.S. Market after Drug Shortage Ends

June 23, 2017
Malaria treatment is the only exemption to the ban. Read More

Indian Drugmaker’s Products Banned From U.S. Market After Drug Shortage Ends

June 21, 2017
The FDA has broadened its import ban against Indian manufacturer Ipca Laboratories to include four drugs previously exempted due to shortage. Only Ipca’s anti-malarial API remains exempted and can be imported into the U.S. Read More

Connecticut Compounder Warned on Unsanitary Conditions and More

June 20, 2017
FDA warned Beacon Prescriptions recently for unsanitary conditions. Read More

FDA Plans Public Workshop to Evaluate Studies of Abuse-Deterrent Opioid Use

June 19, 2017
Two-day meeting will address better uses of data, methodology. Read More

Connecticut Compounder Warned on Unsanitary Conditions and More

June 15, 2017
Beacon Prescriptions, a compounding pharmacy in Southington, Conn., was warned by the FDA for unsanitary conditions and other federal violations, according to a letter sent earlier this month. Read More

Supplement Company Draws Warning Over GMPs

May 31, 2017
The facility lacked specifications for quality control in its supplement manufacturing or packaging operations. Read More

Texas Pharmacy Warned for Using Domperidone

May 30, 2017
The FDA has warned a Texas pharmacy for numerous violations, including compounding unapproved drugs and unsanitary conditions. Read More

Supplement Company Draws Warning Over GMPs

May 25, 2017
A Utah supplement company drew a warning from the FDA for failing to comply with GMP requirements. Read More

PIC/S Hits European Commission Over Relaxed ATMP GMPs

April 12, 2017
An alliance of pharmaceutical regulators has voiced concerns about European Commission draft guidelines relaxing some GMP requirements for advanced therapy medicinal products. Read More

PIC/S Hits European Commission Over Relaxed ATMP GMPs

March 16, 2017
An alliance of pharmaceutical regulators has voiced concerns about European Commission draft guidelines relaxing some GMP requirements for advanced therapy medicinal products. Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 … 58 59 Next

Upcoming Events

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 12May

    Extractables and Leachables: 101

  • 19May

    CDRH’s New Accreditation Scheme for Conformity Assessment: Impacts on Your Future Testing Plans and FDA Submissions

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

  • 27May

    Evolving Clinical Trials: Continuing the Journey from Paper to Digital

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Fujifilm_Logo.gif

    Fujifilm Begins Late-Stage Trial of Avigan for COVID-19

  • CE mark

    DiaSorin’s 10-Minute COVID-19 Antibody Test CE Marked

  • WHO

    WHO Will Review Two COVID-19 Vaccines from China

  • CE mark

    Qiagen’s High Throughput COVID-19 Test Earns CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing